Efficacy results of a trial of a herpes simplex vaccine.
Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, Gorfinkel I, Morrow RL, Ewell MG, Stokes-Riner A, Dubin G, Heineman TC, Schulte JM, Deal CD; Herpevac Trial for Women. N Engl J Med. 2012 Jan 5;366(1):34-43.
In a study population that was representative of the general population of HSV-1–and HSV-2–seronegative women, the investigational vaccine resulted effective in preventing HSV-1 genital disease and infection but not in preventing HSV-2 disease or infection. A point that needs further development is why the biologic characteristics of HSV-1 are different from those of HSV-2: the vaccine induces significant protection against genital HSV-1 disease as well as HSV-1 infection, but not against disease or infection caused by HSV-2. Although the development of a vaccine that provides some protection against HSV-1 genital disease is a substantial step forward, additional progress is needed before a herpes vaccine is likely to be approved for general use.
WHO recommendations for influenza virus vaccine composition for the 2018 southern hemisphere influenza season
The World Health Organization (WHO) has recommended the composition of the trivalent influenza vaccine for the southern hemisphere winter 2018 influenza season in a report published 28 September 2017.Read more
WHO recommendations for influenza virus vaccine composition for the 2017-18 northern hemisphere season
The World Health Organization (WHO) has agreed on the recommended composition of the trivalent influenzaRead more